申请人:Novartis AG
公开号:US06346626B1
公开(公告)日:2002-02-12
The invention concerns the compounds of formula I
wherein
R1 and R2 independently are hydrogen, acyl, alkoxycarbonyl or alkyl; either the sulfamoyloxy side chain is bound to the 6 position;
R3 is alkyl; alkenyl; alkinyl; a cycloalkyl moiety optionally substituted by alkyl, alkoxy or halogen; arylalkenyl; arylalkinyl; acyl; cycloalkylalkyl; 3-oxo-2-oxacamphanyl; or is 6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl; and
R4 is hydrogen; alkyl; hydroxy; or alkoxy;
or the sulfamoyloxy side chain is bound to the 7 position;
R3 has the significance indicated above for R4; and
R4 has the significance indicated above for R3;
X is O or S; and the symbol - - - is a single or a double bond;
in free form or salt form.
They can be prepared by sulfamoylation of corresponding hydroxylated compounds, by reduction and/or by N-substitution.
They are indicated for use as pharmaceuticals, particularly in the prophylactic or curative treatment of illnesses responsive to steroid sulfatase inhibition.
该发明涉及式I的化合物,其中R1和R2独立地是氢、酰基、烷氧羰基或烷基;磺酰氧侧链与6位结合;R3是烷基、烯基、炔基、环烷基基团,可选择地被烷基、烷氧基或卤素取代;芳基烯基、芳基炔基、酰基、环烷基烷基、3-氧代-2-氧代樟脑基;或者是6,6-二甲基双环[3.1.1]庚-2-烯基;R4是氢、烷基、羟基或烷氧基;或者磺酰氧侧链与7位结合;R3具有上述R4的含义;R4具有上述R3的含义;X是O或S;符号- - -是单键或双键;以自由形式或盐形式存在。它们可以通过对应的羟基化合物的磺酰化、还原和/或N-取代制备。它们被指定用于制药,特别是在对甾体磺酸酶抑制敏感的疾病的预防或治疗中使用。